A double-blind randomized controlled trial of continuous intravenous ketorolac vs placebo for adjuvant pain control after renal surgery

Gwen M. Grimsby, Sarah P. Conley, Terrence L. Trentman, Erik P Castle, Paul E. Andrews, Laurie A. Mihalik, Joseph G. Hentz, Mitchell R Humphreys

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy and safety of a novel, continuous intravenous infusion of ketorolac, a powerful nonopioid analgesic, for postoperative pain control. Patients and Methods: A prospective, double-blind, randomized, placebo-controlled trial of a continuous infusion of ketorolac tromethamine in 1 L of normal saline vs placebo was performed in 135 patients aged 18 to 75 years after laparoscopic donor nephrectomy or percutaneous nephrolithotomy completed from October 7, 2008, through July 21, 2010. Primary study end points were the 24-hour differences in visual analog pain scores and total narcotic consumption, whereas secondary end points were differences in urine output, serum creatinine level, and hemoglobin level. Results: The study was stopped after randomization of 135 patients (68 in the ketorolac group and 67 in the placebo group) when interim analysis indicated that the difference in mean pain scores between the 2 groups (difference, 0.6) was smaller than the 1-point threshold set forth in the power calculations. No statistically significant change was noted in hemoglobin levels from preoperative to postoperative values (P=.13) or in postoperative serum creatinine levels (P=.13). Conclusion: Although continuous infusion of ketorolac produced only a modest decrease in the use of narcotics, it appears to offer a safe therapeutic option for nonnarcotic pain control.

Original languageEnglish (US)
Pages (from-to)1089-1097
Number of pages9
JournalMayo Clinic Proceedings
Volume87
Issue number11
DOIs
StatePublished - Nov 2012

Fingerprint

Ketorolac
Randomized Controlled Trials
Narcotics
Placebos
Kidney
Pain
Creatinine
Hemoglobins
Ketorolac Tromethamine
Non-Narcotic Analgesics
Percutaneous Nephrostomy
Postoperative Pain
Random Allocation
Nephrectomy
Serum
Intravenous Infusions
Tissue Donors
Urine
Safety
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A double-blind randomized controlled trial of continuous intravenous ketorolac vs placebo for adjuvant pain control after renal surgery. / Grimsby, Gwen M.; Conley, Sarah P.; Trentman, Terrence L.; Castle, Erik P; Andrews, Paul E.; Mihalik, Laurie A.; Hentz, Joseph G.; Humphreys, Mitchell R.

In: Mayo Clinic Proceedings, Vol. 87, No. 11, 11.2012, p. 1089-1097.

Research output: Contribution to journalArticle

Grimsby, Gwen M. ; Conley, Sarah P. ; Trentman, Terrence L. ; Castle, Erik P ; Andrews, Paul E. ; Mihalik, Laurie A. ; Hentz, Joseph G. ; Humphreys, Mitchell R. / A double-blind randomized controlled trial of continuous intravenous ketorolac vs placebo for adjuvant pain control after renal surgery. In: Mayo Clinic Proceedings. 2012 ; Vol. 87, No. 11. pp. 1089-1097.
@article{2e91be0d9f2f42aaa3f21c36e9fd0587,
title = "A double-blind randomized controlled trial of continuous intravenous ketorolac vs placebo for adjuvant pain control after renal surgery",
abstract = "Objective: To evaluate the efficacy and safety of a novel, continuous intravenous infusion of ketorolac, a powerful nonopioid analgesic, for postoperative pain control. Patients and Methods: A prospective, double-blind, randomized, placebo-controlled trial of a continuous infusion of ketorolac tromethamine in 1 L of normal saline vs placebo was performed in 135 patients aged 18 to 75 years after laparoscopic donor nephrectomy or percutaneous nephrolithotomy completed from October 7, 2008, through July 21, 2010. Primary study end points were the 24-hour differences in visual analog pain scores and total narcotic consumption, whereas secondary end points were differences in urine output, serum creatinine level, and hemoglobin level. Results: The study was stopped after randomization of 135 patients (68 in the ketorolac group and 67 in the placebo group) when interim analysis indicated that the difference in mean pain scores between the 2 groups (difference, 0.6) was smaller than the 1-point threshold set forth in the power calculations. No statistically significant change was noted in hemoglobin levels from preoperative to postoperative values (P=.13) or in postoperative serum creatinine levels (P=.13). Conclusion: Although continuous infusion of ketorolac produced only a modest decrease in the use of narcotics, it appears to offer a safe therapeutic option for nonnarcotic pain control.",
author = "Grimsby, {Gwen M.} and Conley, {Sarah P.} and Trentman, {Terrence L.} and Castle, {Erik P} and Andrews, {Paul E.} and Mihalik, {Laurie A.} and Hentz, {Joseph G.} and Humphreys, {Mitchell R}",
year = "2012",
month = "11",
doi = "10.1016/j.mayocp.2012.07.018",
language = "English (US)",
volume = "87",
pages = "1089--1097",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "11",

}

TY - JOUR

T1 - A double-blind randomized controlled trial of continuous intravenous ketorolac vs placebo for adjuvant pain control after renal surgery

AU - Grimsby, Gwen M.

AU - Conley, Sarah P.

AU - Trentman, Terrence L.

AU - Castle, Erik P

AU - Andrews, Paul E.

AU - Mihalik, Laurie A.

AU - Hentz, Joseph G.

AU - Humphreys, Mitchell R

PY - 2012/11

Y1 - 2012/11

N2 - Objective: To evaluate the efficacy and safety of a novel, continuous intravenous infusion of ketorolac, a powerful nonopioid analgesic, for postoperative pain control. Patients and Methods: A prospective, double-blind, randomized, placebo-controlled trial of a continuous infusion of ketorolac tromethamine in 1 L of normal saline vs placebo was performed in 135 patients aged 18 to 75 years after laparoscopic donor nephrectomy or percutaneous nephrolithotomy completed from October 7, 2008, through July 21, 2010. Primary study end points were the 24-hour differences in visual analog pain scores and total narcotic consumption, whereas secondary end points were differences in urine output, serum creatinine level, and hemoglobin level. Results: The study was stopped after randomization of 135 patients (68 in the ketorolac group and 67 in the placebo group) when interim analysis indicated that the difference in mean pain scores between the 2 groups (difference, 0.6) was smaller than the 1-point threshold set forth in the power calculations. No statistically significant change was noted in hemoglobin levels from preoperative to postoperative values (P=.13) or in postoperative serum creatinine levels (P=.13). Conclusion: Although continuous infusion of ketorolac produced only a modest decrease in the use of narcotics, it appears to offer a safe therapeutic option for nonnarcotic pain control.

AB - Objective: To evaluate the efficacy and safety of a novel, continuous intravenous infusion of ketorolac, a powerful nonopioid analgesic, for postoperative pain control. Patients and Methods: A prospective, double-blind, randomized, placebo-controlled trial of a continuous infusion of ketorolac tromethamine in 1 L of normal saline vs placebo was performed in 135 patients aged 18 to 75 years after laparoscopic donor nephrectomy or percutaneous nephrolithotomy completed from October 7, 2008, through July 21, 2010. Primary study end points were the 24-hour differences in visual analog pain scores and total narcotic consumption, whereas secondary end points were differences in urine output, serum creatinine level, and hemoglobin level. Results: The study was stopped after randomization of 135 patients (68 in the ketorolac group and 67 in the placebo group) when interim analysis indicated that the difference in mean pain scores between the 2 groups (difference, 0.6) was smaller than the 1-point threshold set forth in the power calculations. No statistically significant change was noted in hemoglobin levels from preoperative to postoperative values (P=.13) or in postoperative serum creatinine levels (P=.13). Conclusion: Although continuous infusion of ketorolac produced only a modest decrease in the use of narcotics, it appears to offer a safe therapeutic option for nonnarcotic pain control.

UR - http://www.scopus.com/inward/record.url?scp=84872236594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872236594&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2012.07.018

DO - 10.1016/j.mayocp.2012.07.018

M3 - Article

C2 - 23058854

AN - SCOPUS:84872236594

VL - 87

SP - 1089

EP - 1097

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 11

ER -